JPRN-UMIN000004214已完成未知
Phase II, Randomized, Double-Blind ,Placebo-Controlled Study of Hangeshashinto for Prevention of Oral Mucositis in Gastric Cancer Patients Receiving Chemotherapy (HANGESHA-G Study). - Study of Hangeshashinto for Prevention of Oral Mucositis in Gastric Cancer Patients Receiving Chemotherapy (HANGESHA-G Study).
PO Epidemiological and Clinical Research Information Network (ECRIN)0 个研究点目标入组 90 人开始时间: 2010年10月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients who had received blood transfusion, blood products, or hematopoietic growth factors such as granulocyte-colony stimulating factor within 7 days prior to registration. (2)Patients who had used traditional Japanese medicines (Kampo) within 2 weeks before registration. (3)History of severe hypersensitivity (allergy) to any medicines. (4)Patients who had received antiphlogistic analgetic, opioid, or steroid. (5)Prior or current therapy for neuropathy or sensory dysfunction. (6)Other active malignancies. (7)Uncontrolled pleural effusion or ascites. (8)A systemic inflammatory condition or serious infection. (9)Brain metastasis. (10)Significant electrocardiographic abnormality. (11)Clinically problematic cardiac disease (congestive heart failure, symptomatic coronary artery disease, uncontrolled arrhythmia, or myocardial infarction within the past 12 months). (12)Severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, pulmonary emphysema, etc.). (13)Gastrointestinal bleeding that requires medication or transfusion. (14)Diarrhea (watery) or diarrhea that interferes with daily activities for patients with a stoma. (15)Myelosuppresion. (16)Ileus or bowel obstruction. (17)Central nervous system disorders. (18)Dementia. (19)Serious psychological disease. (20)Uncontrolled diabetes mellitus with or without diabetic neuropathy. (21)Serious constipation. (22)Pregnant or lactating women. (23)Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of ANB019 in Subjects with IchthyosisMedDRA version: 21.0Level: LLTClassification code 10037159Term: Psoriasis pustularSystem Organ Class: 100000004858IchthyosisEUCTR2020-003476-41-PLAnaptysBio Inc.24
进行中（未招募）
不适用
Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate Crohn's diseaseCrohn’s DiseaseMedDRA version: 17.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-001892-30-BEGalapagos NV120
进行中（未招募）
1 期
Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative ColitisEUCTR2014-001893-32-CZGalapagos NV60
进行中（未招募）
不适用
Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative ColitisEUCTR2014-001893-32-HUGalapagos NV60
进行中（未招募）
不适用
Placebo-controlled study to assess efficicay, safety and tolerability and to investigate the pharmacokinetics of GLPG1205 in subjects with moderate to severe Ulcerative Colitislcerative ColitisMedDRA version: 18.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2014-001893-32-PLGalapagos NV60